Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
11:56am, Thursday, 05'th Nov 2020
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
Axsome Therapeutics and Veeva Systems Partner to Build Axsome's Digital-Centric Commercialization™ Platform
07:03am, Wednesday, 04'th Nov 2020
Collaboration provides Axsome access to new digital technologies developed by Veeva
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
07:00am, Wednesday, 28'th Oct 2020
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time
IPO Update: Harmony Biosciences Seeks $100 Million IPO (Pending:HRMY)
09:45pm, Tuesday, 11'th Aug 2020
Harmony Biosciences intends to raise $100 million in an IPO. The firm is developing and commercializing treatments for narcolepsy and related conditions.
Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses
05:05pm, Tuesday, 11'th Aug 2020
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.
Why Axsome Therapeutics Stock Rose Today
08:44pm, Monday, 10'th Aug 2020
The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
11:05am, Monday, 10'th Aug 2020
Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020 Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3 lon
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
11:00am, Monday, 10'th Aug 2020
Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
11:00am, Wednesday, 05'th Aug 2020
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsyThird FDA Breakthrough Therapy designation received
Axsome Therapeutics: Big Unfolding Catalyst (NASDAQ:AXSM)
09:19am, Wednesday, 05'th Aug 2020
Axsome continues to deliver a flurry of positive catalysts for various pipeline molecules. Despite subpar data for the treatment-resistant depression, AXS-05 generated extremely robust results for oth
BidaskClub Downgrades Axsome Therapeutics (NASDAQ:AXSM) to Sell
05:16am, Monday, 03'rd Aug 2020
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday, BidAskClub reports. Several othe
Harmony Biosciences Starts U.S. IPO Effort
12:23pm, Friday, 31'st Jul 2020
Harmony Biosciences has filed to raise $100 million in an IPO, although the final figure will likely differ.
